Grail (NASDAQ:GRAL – Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($1.86) EPS for the quarter, beating the consensus estimate of ($4.41) by $2.55, Zacks reports. The business had revenue of $38.25 million for the quarter, compared to analyst estimates of $35.33 million.
Grail Price Performance
Shares of NASDAQ GRAL opened at $40.73 on Friday. The firm has a fifty day moving average of $26.32 and a 200 day moving average of $19.06. Grail has a one year low of $12.33 and a one year high of $63.99.
Analysts Set New Price Targets
GRAL has been the subject of several recent research reports. Wolfe Research initiated coverage on shares of Grail in a report on Friday, November 15th. They set a “peer perform” rating for the company. Morgan Stanley initiated coverage on shares of Grail in a report on Wednesday, November 27th. They set an “equal weight” rating and a $16.00 target price for the company.
About Grail
GRAIL, Inc is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.
Further Reading
- Five stocks we like better than Grail
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- DuPont’s Electronics Spinoff: The Start of Something Big
- How to Find Undervalued Stocks
- The Trade Desk Crashes on Earnings, But Growth Catalysts Persist
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Market Shift: These 3 Stocks Are Winning While Big Tech Lags
Receive News & Ratings for Grail Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grail and related companies with MarketBeat.com's FREE daily email newsletter.
